Adient (NYSE:ADNT) Receives $17.31 Consensus Price Target from Brokerages

Shares of Adient (NYSE:ADNT - Get Free Report) have received an average rating of "Reduce" from the nine research firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $17.31.

Several equities research analysts have recently commented on ADNT shares. Citigroup started coverage on shares of Adient in a research report on Wednesday, April 23rd. They set a "neutral" rating and a $14.00 price target for the company. Wall Street Zen lowered shares of Adient from a "buy" rating to a "hold" rating in a research report on Saturday, June 14th. Barclays lowered shares of Adient from an "equal weight" rating to a "negative" rating in a research report on Tuesday, April 15th. Morgan Stanley reduced their price target on shares of Adient from $17.00 to $16.00 and set an "underweight" rating for the company in a research report on Monday, May 19th. Finally, Wells Fargo & Company increased their target price on shares of Adient from $17.00 to $18.00 and gave the stock an "equal weight" rating in a report on Tuesday.

Adient Stock Performance

NYSE:ADNT traded up $0.20 during mid-day trading on Wednesday, reaching $22.38. The company's stock had a trading volume of 867,910 shares, compared to its average volume of 1,458,878. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 1.22. The stock has a market cap of $1.88 billion, a P/E ratio of -6.99, a PEG ratio of 0.49 and a beta of 1.69. The firm's fifty day moving average price is $16.59 and its two-hundred day moving average price is $15.69. Adient has a 12-month low of $10.04 and a 12-month high of $26.59.

Adient (NYSE:ADNT - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.33. The business had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.39 billion. Adient had a negative net margin of 1.86% and a positive return on equity of 7.70%. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.54 EPS. On average, equities analysts forecast that Adient will post 1.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ADNT. Covestor Ltd lifted its position in Adient by 10.6% in the fourth quarter. Covestor Ltd now owns 6,062 shares of the company's stock worth $104,000 after buying an additional 580 shares during the last quarter. Mariner LLC lifted its position in Adient by 8.6% in the fourth quarter. Mariner LLC now owns 10,157 shares of the company's stock worth $175,000 after buying an additional 801 shares during the last quarter. GAMMA Investing LLC lifted its position in Adient by 157.5% in the first quarter. GAMMA Investing LLC now owns 2,235 shares of the company's stock worth $29,000 after buying an additional 1,367 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in Adient in the fourth quarter worth $25,000. Finally, Oarsman Capital Inc. lifted its position in Adient by 98.7% in the fourth quarter. Oarsman Capital Inc. now owns 2,966 shares of the company's stock worth $51,000 after buying an additional 1,473 shares during the last quarter. 92.44% of the stock is currently owned by institutional investors.

About Adient

Adient plc engages in the design, development, manufacture, and market of seating systems and components for passenger cars, commercial vehicles, and light trucks. The company's automotive seating solutions include complete seating systems, frames, mechanisms, foams, head restraints, armrests, and trim covers.